Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Novartis Vows Continued Reforms despite Not-Guilty Diovan Ruling
March 17, 2017
- Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
- Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief
March 16, 2017
- Lilly’s Japan Sales Keep Momentum in 2016 with 3.1% Rise
March 16, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Takeda Revving Up Partnership Initiatives
March 15, 2017
- Maruho Gets Global Rights to Toray’s RORγt Inhibitor
March 15, 2017
- Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
- Kissei, Maruishi Join Hands on Opioid Receptor Agonist
March 14, 2017
- INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
- Daiichi Sankyo Taps Heptares for Pain Med Discovery Research
March 14, 2017
- Daiichi Sankyo Launches Large-Scale Observational Study for Cancer VTE
March 14, 2017
- Toyama Chemical, Towa Settle Patent Suit over Ozex Pediatric Drug
March 14, 2017
- Canada’s Duchesnay Gets Rights to Shionogi’s Osphena in North America
March 14, 2017
- Debiopharm Brings Towa before Supreme Court over Elplat
March 14, 2017
- 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
March 14, 2017
- Yoshiki Ito Named as New Alexion Japan President
March 14, 2017
- Pfizer Initiates Voluntary Recall of EpiPen 0.3 mg in Japan
March 14, 2017
- UMN, Astellas Agree on Termination of Joint Flu Vaccine Programs
March 13, 2017
- Eisai CEO Has High Hopes on Combinations of Alzheimer’s Pipelines
March 10, 2017
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…